Welcome to GeneCentric Diagnostics, Inc.
GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou’s laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine.
GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric’s second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.
GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.
|New targeted therapies have changed the need for classifying lung cancer, primarily for distinguishing the non-squamous from squamous forms of non-small cell lung cancer (NSCLC).||GeneCentric has exclusive worldwide commercial right to a 13-gene VEGF signature associated with distant metastases and poor outcomes (“Hypoxia Signature”).||October 15, 2012 – Dr. Myla Lai-Goldman was recently interviewed by CEOCFO Magazine about the GeneCentric technology known as the Lung Subtype Platform.